The online version of this article (doi:10.1186/1476-7961-10-7) contains supplementary material, which is available to authorized users.
Francesco Marcucci and Cristoforo Incorvaia are scientific consultants for Stallergenes Italy.
Ilaria Dell’Albani and Franco Frati are employees of Stallergenes Italy.
FM conceived the study, participated in its design and analysed the results. LS participated in the study design and carried out the tests. CI analysed the results and participated to writing the manuscript. ID participated to writing the manuscript. GD carried out the tests, analysed the results and participated to writing the manuscript. FF participated in the study design, analysed the results and participated to writing the manuscript. All authors read and approved the final manuscript.
Grass pollen is a major cause of respiratory allergy worldwide and contain a number of allergens, some of theme (Phl p 1, Phl p 2, Phl p 5, and Phl 6 from Phleum pratense, and their homologous in other grasses) are known as major allergens. The administration of grass pollen extracts by immunotherapy generally induces an initial rise in specific immunoglobulin E (sIgE) production followed by a progressive decline during the treatment. Some studies reported that immunotherapy is able to induce a de novo sensitisation to allergen component previously unrecognized.
We investigated in 30 children (19 males and 11 females, mean age 11.3 years), 19 treated with sublingual immunotherapy (SLIT) by a 5-grass extract and 11 untreated, the sIgE and sIgG4 response to the different allergen components.
Significant increases (p < 0.001) were detected for Phl p 1, Phl p 2, Phl p 5, and Phl p 6, while sIgE levels induced in response to Phl p 7 and Phl p 12 were low or absent at baseline and unchanged following SLIT treatment; no new sensitisation was detected. As to IgG4, significant increases were found for Phl p2 and Phl p 5, while the increase for Phl p 12 was not significant. In the control group, no significant increase in sIgE for any single allergen component was found.
These findings confirm that the initial phase of SLIT with a grass pollen extract enhances the sIgE synthesis and show that the sIgE response concerns the same allergen components which induce IgE reactivity during natural exposure.
Freye HB: The role of pollens in allergy. Med Health R I. 2008, 91: 174-175. PubMed
Hrabina M, Peltre G, van Ree R, Moingeon P: Grass pollen allergens. Clin Exp Allergy Rev. 2008, 8: 7-11. 10.1111/j.1472-9733.2008.00126.x. CrossRef
Didier A, Malling HJ, Worm M, Horak F, Jager S, Montagut A, André C, de Beaumont O, Melac M: Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol. 2007, 120: 1338-1345. 10.1016/j.jaci.2007.07.046 CrossRefPubMed
Horak F, Zieglmayer P, Zieglmayer R, Lemell P, Devillier P, Montagut A, Melac M, Galvain S, Jean-Alphonse S, van Overtvelt L, Moingeon P, Le Gall M: Early onset of action of a 5-grass pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J Allergy Clin Immunol. 2009, 124: 471-477. 10.1016/j.jaci.2009.06.006 CrossRefPubMed
Malling HJ, Lund L, Ipsen H, Poulsen L: Safety and immunological changes during sublingual immunotherapy with standardized quality grass allergen tablets. J Investig Allergol Clin Immunol. 2006, 16: 162-168. PubMed
Ball T, Sperr WR, Valent P, Lidholm J, Spitzauer S, Ebner C, Kratf D, Valenta R: Induction of antibody response to new B cell epitopes indicates vaccine character of allergen immunotherapy. Eur J Immunol. 1999, 29: 2026-2036. 10.1002/(SICI)1521-4141(199906)29:06<2026::AID-IMMU2026>3.0.CO;2-2 CrossRefPubMed
Rossi RE, Monasterolo G: Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11. 12, and nPhl p 4) –specific antibodies induced by subcutaneous timothy pollen extract immunotherapy in allergic patients. Int Arch Allergy Immunol. 2004, 135: 44-53. 10.1159/000080042 CrossRefPubMed
Gadermaier E, Staikuniene J, Scheiblhofer S, Thalhamer J, Kundi M, Westritschnig K, Swoboda I, Flicker S, Valenta R: Recombinant allergen-based monitoring of antibody responses during injection grass pollen immunotherapy and after 5 years of discontinuation. Allergy. 2011, 66: 1174-1182. 10.1111/j.1398-9995.2011.02592.x CrossRefPubMed
Aberer W, Hawranek T, Reider N, Schuster C, Sturm G, Kranke B: Immunoglobulin E and G antibody profiles to grass pollen allergens during a short course of sublingual immunotherapy. J Investig Allergol Clin Immunol. 2007, 17: 131-136. PubMed
Bousquet J, van Cauwenberge P, Khaltaev N, : World Health Organization: Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001, 108 (suppl 5)): 147-334. CrossRef
Moverare R, Elfman L, Vesterinen E, Metso T, Haahtela T: Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System. Allergy. 2002, 57: 423-430. 10.1034/j.1398-9995.2002.13248.x CrossRefPubMed
Halken S, Agertoft L, Seidenberg J, Bauer CB, Payot F, Martin-Munoz MF, Bartkowiak-Emeryk M, Vereda A, Jean-Alphonse S, Melac M, Le Gall M, Wahn U: Five-grass pollen 300IR SLIT tablets: efficacy and safety in children and adolescents. Pediatr Allergy Immunol. 2010, 21: 970-976. 10.1111/j.1399-3038.2010.01050.x CrossRefPubMed
Tripodi S, Frediani T, Lucarelli S, Macrì F, Pingitore G, Di Rienzo-Businco A, Dondi A, Pansa P, Ragusa G, Asero R, Faggian D, Plebani M, Matricardi PM: Molecular profiles of IgE to Phleum pratense in children with grass pollen allergy: implications for specific immunotherapy. J Allergy Clin Immunol. 2012, 129: 834-839. 10.1016/j.jaci.2011.10.045 CrossRefPubMed
- Specific IgE response to different grass pollen allergen components in children undergoing sublingual immunotherapy
Giuseppe Di Cara
- BioMed Central
Neu im Fachgebiet HNO
e.Med Kampagnen-Visual, Mail Icon II